Analyzing Copernicus Capital's Q2 vs. Q3 2021 13F Holdings: Winners and Losers

Copernicus Capital Management, LLC released its latest 13F filings, revealing the company's holdings as of Q3 2021. The report compares the holdings of Q2 2021 to Q3 2021, indicating the changes in shares, values, and percentage change. In this article, we will delve deeper into the report's findings and analyze the winners and losers of the quarter from the company's perspective.

Pfizer Inc (PFE) was the company's biggest gainer, with an outstanding 30,000 shares added, which is an impressive 100% increase from Q2 2021. This move helped Copernicus Capital Management, LLC increase its value from $0 in Q2 2021 to $1.29M in Q3 2021. Thermo Fisher Scientific Inc (TMO) also fared well with 2,000 shares added, and the value of shares rose from $0 to $1.14M - an increase of 100%.

Teladoc Health Inc (TDOC) and Biomarin Pharmaceutical Inc (BMRN) also recorded gains with 7,000 and 11,000 shares respectively, increasing their total value by 100%. Johnson & Johnson (JNJ) saw an addition of 5,000 shares, increasing the total value by 100%.

While some companies experienced gains, others experienced losses. Fate Therapeutics Inc. (FATE) had the most significant loss, which could be attributed to the decision to cover shorts and cut losses. Copernicus Capital Management, LLC lost an estimated $157,000 following an 18.1% drop. Horizon Therapeutics Pub L (HZNP) suffered the lowest loss with a 40.4% decrease in the value of shares.

The significant movers in the report include Arcus Biosciences Inc (RCUS), ProQR Thrapeutics N V (PRQR), and Immatrics N.V (IMTX). RCUS experienced significant growth following the addition of 3,000 shares, increasing the total value by 259.4%. PRQR saw an impressive 400% gain, adding 40,000 shares and increasing the total value by 100%. IMTX added 10,000 shares, with the total value increasing by 100%.

The remaining companies, including Vertex Pharmaceuticals Inc (VRTX), Atara Biotherapeutics Inc (ATRA), and Zentais Pharmaceuticals Inc (ZNTL), reported a 100% decrease in the value of shares. Copernicus Capital Management, LLC sold all their shares with these companies, resulting in a loss of $1.1M.

In conclusion, the Copernicus Capital Management, LLC's Q2 vs. Q3 2021 13F holdings report indicates gains and losses from the company's perspective. The report provides insights into the decisions taken by the firm's management and adds possibilities for investors to review their respective portfolios. Investing wisely means staying updated and informed about such important financial reports, as it can influence the direction and growth of an investment portfolio.